Abstract
We have studied the disposition of bleomycin, melphalan, or vinblastine after intraperitoneal (IP) instillation in 14 cancer patients. Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose. IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration. Melphalan's systemic absorption form the IP space averaged only 39% of the administered dose. In contrast, vinblastine plasma levels remained elevated for longer than 24 h after IP instillation. Its use was associated with life-threatening adynamic ileus in two patients. Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 293-299 |
| Number of pages | 7 |
| Journal | Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer |
| Volume | 74 |
| State | Published - 1980 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. / Alberts, David S; Chen, H. S.; Chang, S. Y.; Peng, Y. M.
In: Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer, Vol. 74, 1980, p. 293-299.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.
AU - Alberts, David S
AU - Chen, H. S.
AU - Chang, S. Y.
AU - Peng, Y. M.
PY - 1980
Y1 - 1980
N2 - We have studied the disposition of bleomycin, melphalan, or vinblastine after intraperitoneal (IP) instillation in 14 cancer patients. Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose. IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration. Melphalan's systemic absorption form the IP space averaged only 39% of the administered dose. In contrast, vinblastine plasma levels remained elevated for longer than 24 h after IP instillation. Its use was associated with life-threatening adynamic ileus in two patients. Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses.
AB - We have studied the disposition of bleomycin, melphalan, or vinblastine after intraperitoneal (IP) instillation in 14 cancer patients. Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose. IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration. Melphalan's systemic absorption form the IP space averaged only 39% of the administered dose. In contrast, vinblastine plasma levels remained elevated for longer than 24 h after IP instillation. Its use was associated with life-threatening adynamic ileus in two patients. Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses.
UR - http://www.scopus.com/inward/record.url?scp=0019280928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019280928&partnerID=8YFLogxK
M3 - Article
C2 - 6160601
AN - SCOPUS:0019280928
VL - 74
SP - 293
EP - 299
JO - Recent Results in Cancer Research
JF - Recent Results in Cancer Research
SN - 0080-0015
ER -